Critical Care
(Oct 2020)
Infliximab can reduce mortality from 35 to 14% in critically ill patients with COVID-19: perhaps some potential confounders to consider
- Patrick M. Honore,
- Leonel Barreto Gutierrez,
- Luc Kugener,
- Sebastien Redant,
- Rachid Attou,
- Andrea Gallerani,
- David De Bels
Affiliations
- Patrick M. Honore
- ICU Department, Centre Hospitalier Universitaire Brugmann-Brugmann University Hospital
- Leonel Barreto Gutierrez
- ICU Department, Centre Hospitalier Universitaire Brugmann-Brugmann University Hospital
- Luc Kugener
- ICU Department, Centre Hospitalier Universitaire Brugmann-Brugmann University Hospital
- Sebastien Redant
- ICU Department, Centre Hospitalier Universitaire Brugmann-Brugmann University Hospital
- Rachid Attou
- ICU Department, Centre Hospitalier Universitaire Brugmann-Brugmann University Hospital
- Andrea Gallerani
- ICU Department, Centre Hospitalier Universitaire Brugmann-Brugmann University Hospital
- David De Bels
- ICU Department, Centre Hospitalier Universitaire Brugmann-Brugmann University Hospital
- DOI
-
https://doi.org/10.1186/s13054-020-03294-7
- Journal volume & issue
-
Vol. 24,
no. 1
pp.
1
– 2
WeChat QR code
